Merck faces another round of criticism

Philadelphia Inquirer, August 19, 2008

For the third time in three years, a prominent medical journal has criticized Merck & Co. Inc. for misrepresenting research on its pain reliever Vioxx. The editors of the Annals of Internal Medicine said the journal's findings may point to a broader problem in the pharmaceutical industry. Drug companies have long been suspected of enlisting doctors in trials solely to get doctors in the "habit of prescribing a new drug," the editors said. These are known as "seeding" trials, and the editorial says such trials pay doctors involved in them to consult with the drug company plus a fee for each patient they enroll.


MOST POPULAR

SPONSORED REPORTS
SPONSORED HEADLINES

SIGN UP

FREE e-Newsletters Join the Council Subscribe to HL magazine

SPONSORSHIP & ADVERTISING

100 Winners Circle Suite 300
Brentwood, TN 37027

800-727-5257

About | Advertise | Terms of Use | Privacy Policy | Reprints/Permissions | Contact
© HealthLeaders Media 2015 a division of BLR All rights reserved.